leadf
logo-loader
viewBenchmark Holdings PLC

Benchmark sees long-term growth in aquaculture

Snapshot

  • Huge potential for aquaculture as the world's population grows but sea fish numbers fall
  • New products to be launched that provide environmentally friendly treatments
  • In 2020 raised £43mln to take new products to market 
salmon

Quick facts: Benchmark Holdings PLC

Price: 47.255 GBX

AIM:BMK
Market: AIM
Market Cap: £315.51 m
Follow

What Benchmark Holdings does

Benchmark Holdings PLC (LON:BMK) has three core divisions, genetics – which includes salmon eggs with traits such as disease resistance, growth and quality.

The Advanced Nutrition division specialises in feeding the young animals including probiotics to build resilience through the early life stages, while Animal Health tackles serious issues such as sea lice in fish farming.

The company believes its new sea lice medicine together with its purification system, CleanTreat, have the potential to be transformational for the industry, providing a solution with "zero environmental impact to one of the industry's biggest challenges".

How it's doing

For the three months ended June 30, the firm reported adjusted earnings (EBITDA) from continuing operations of £300,000, swinging from a £1.4mln loss a year ago, while revenues rose to £24.5mln from £22.8mln.

The company said its genetics business had seen “continued good performance” during the period, while its advanced nutrition division had also seen higher revenues as it benefitted from a partial catch-up of orders that were delayed due to the coronavirus.

Looking ahead, Benchmark said the salmon industry “remains resilient” with stable sea bass and sea bream markets, although conditions in the shrimp market were “challenging” and they expected these trends to continue into its 2021 financial year.

The group also expects to deliver full-year results that are in line with market expectations.

The company also made progress in July when it completed the sale of its vaccine manufacturing facility at Braintree in the UK to Cell and Gene Therapy Catapult for £16mln in cash.

What the boss says, chief executive Trond Williksen

"We are very pleased with the significant progress made over the last few months towards the completion of the disposal of non-core assets and the cash proceeds generated. Following the restructuring, we are well advanced to become a streamlined, financially strong business wholly focused on our core businesses: Genetics, Advanced Nutrition and Health.

We continue to work on our restructuring programme which aims to deliver £10mln in annual savings from [the 2021 financial year] taking us a step closer towards our goal of becoming sustainably profitable.”

"While the shrimp market continues to experience challenges as a result of [coronavirus] the salmon market, which underpins our genetics and health businesses, remains resilient and overall, we expect to deliver full-year results in line with expectations."

Video Interview - chairman Peter George

Blue Sky

Fundamentals remain firmly in the company’s favour: 

The fishing industry has just about reached the limit of what it can catch in the sea and might even be in decline

Seafood is increasingly acknowledged as an essential component of healthy diets

The growing middle-classes in the southern hemisphere, traditionally a fish-eating culture, are spending evermore.

A growing global population needs more food to be produced from the water

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Benchmark Holdings PLC named herein, including the promotion by the Company of Benchmark Holdings PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Open Orphan first half: 'period of integration, restructuring and setting...

Proactive Analyst Emma Ulker talks through how Open Orphan (LON:ORPH) performed in the first half of the year.  In the six-month period to June 2020, the company focused on integration and restructuring following its acquisition of lab services and challenge studies specialist hVIVO in...

3 weeks, 1 day ago

3 min read